Egeberg, Alexander http://orcid.org/0000-0001-8257-1816
Linsell, Louise
Johansson, Erin
Durand, Frederick
Yu, Guanglei
Vañó-Galván, Sergio
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 11 July 2023
Accepted: 14 September 2023
First Online: 13 October 2023
Declarations
:
: Alexander Egeberg has received research funding from Almirall, Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb, AbbVie, Janssen Pharmaceuticals, Boehringer Ingelheim, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as a consultant and/or speaker from Amgen, AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen Pharmaceuticals. Louise Linsell is an employee of Visible Analytics, Oxford, UK. Sergio Vañó-Galván is an advisor for Pfizer and Eli Lilly and Company. Erin Johansson, Frederick Durand, and Guanglei Yu are employees and minor shareholders of Eli Lilly and Company.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.